Roth Capital


Superior Drilling Products Receives New Coverage From Analyst At Roth Capital

Roth Capital analyst Joseph Reagor initiated coverage on shares of Superior Drilling Products Co. (SDPI) in a research note issued this morning.

Seeking Alpha Article On Ligand Pharmaceuticals Just Foolish, Says Roth Capital Analyst

A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based …

Galena Reiterated With A Buy At Roth Capital Following Enrollment Completion In Phase IIa Study

In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …

Roth Capital Reiterates Buy Rating On Can-Fite Following The Completion Of Patients Enrollment

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated coverage on Can-Fite Bio Pharma (CANF) with a Buy rating and a $28.00 price target.

Roth Capital Sees An Attractive Buying Opportunity In Motorcar Parts of America

In a research note issued today, Roth Capital analyst Philip Shen reiterated coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA), and a …

Roth Capital Initiates Research Coverage On Fusion IO Inc. With A Buy Rating

Roth Capital initiated coverage on Fusion IO Inc. (FIO) with a Buy rating and $12.

Intel Corporation Upgraded to Buy From Neutral At Roth Capital

Analyst Krishna Shankar of Roth Capital upgraded Intel Corporation (INTC) from Neutral to Buy, and boosted his price target on INTC from $28.00 to $35.

Roth Capital Maintains Buy Rating On Uranium Resources

Roth Capital reiterated coverage yesterday on Uranium Resources Inc. (URRE) with a Buy rating and $4.

UPDATE: Roth Capital Resumes Coverage On Conatus Pharmaceuticals

In a report published today, Roth Capital analyst Ed Arce resumed coverage on Conatus Pharmaceuticals Inc. (CNAT) with a Buy rating and $19.

We See An Attractive Risk/Reward In MPAA Shares, Says Roth Capital Analyst

In a research note issued this morning, Roth Capital maintained coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA) and a price target of $30.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts